GlassScriptPhysician profile
Kaitlin R Roslen
NPI 1659756286
$6,284.64
in general payments reported to CMS, 2019-2025
28 companies · $1,975 in 2025
The $1,975 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,203 · 2022: $755 · 2023: $1,854 · 2024: $497 · 2025: $1,975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,242 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,242.00 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,970.60 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $805.81 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $765.61 | 2021-2025 | Entyvio |
| Janssen Biotech, INC. | $664.17 | 2021-2025 | Tremfya, Stelara, Remicade |
| Madrigal Pharmaceuticals | $504.65 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $211.59 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $206.97 | 2021-2025 | Ocaliva |
| Braintree Laboratories, INC. | $141.63 | 2021-2024 | Suflave, Sutab |
| Pfizer INC. | $113.53 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $113.40 | 2021-2024 | Linzess |
| Amgen INC. | $102.07 | 2021-2023 | Avsola, Amjevita |
| Gilead Sciences, INC. | $89.06 | 2022 | |
| Genzyme Corporation | $80.09 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $59.94 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $48.94 | 2025 | Iqirvo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.47 | 2023 | Cyltezo |
| Daiichi Sankyo INC. | $47.41 | 2021 | |
| Aimmune Therapeutics, INC. | $45.79 | 2025 | Zenpep |
| Celgene Corporation | $42.04 | 2021-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $39.63 | 2022-2023 | Dupixent |
| Lilly USA, LLC | $35.60 | 2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $28.94 | 2022-2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $26.12 | 2024-2025 | Voquezna |
| Ethicon US, LLC | $24.26 | 2021 | |
| Merck Sharp & Dohme LLC | $21.52 | 2023 | Dificid |
| Fresenius Kabi USA, LLC | $18.88 | 2023 | Idacio |
| Organon LLC | $16.42 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $12.50 | 2024 | Cold Snares |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlin Roslen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.